This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2024. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.
| Item | Value |
|---|---|
| Country | United States |
| Wikipedia page | https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation |
| Best overview URL | https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation |
| Facebook username | gatesfoundation |
| LinkedIn username | bill-&-melinda-gates-foundation |
| Website | https://www.gatesfoundation.org/ |
| Donations URL | https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database |
| Twitter username | gatesfoundation |
| Page on philosophy informing donations | https://www.gatesfoundation.org/What-We-Do |
| Grant application process page | https://www.gatesfoundation.org/How-We-Work/General-Information/Grantseeker-FAQ |
| Regularity with which donor updates donations data | continuous updates |
| Regularity with which Donations List Website updates donations data (after donor update) | irregular |
| Lag with which donor updates donations data | months |
| Lag with which Donations List Website updates donations data (after donor update) | years |
| Data entry method on Donations List Website | SQL insertion commands generated by script https://github.com/riceissa/gates-foundation-iati-processing |
Brief history: The Gates Foundation launched in 2000, with precursors starting in the 1990s, financed by the personal wealth of co-founder Bill Gates from Microsoft. Starting 2005, it scaled up its giving significantly after a large funding commitment from Warren Buffett
Brief notes on broad donor philosophy and major focus areas: See https://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet for the grantmaking areas. The four grantmaking areas are the Global Development Program, Global Health Program, Global Policy and Advocacy, and United States Program. Within the United States Program the focus is on K-12 education, the Internet, and emergency relief
Notes on grant publication logistics: Although the Gates Foundation has a grants database on its website, as well as individual grant pages for every grant, we use the IATI data instead, because it can be processed programmatically (the data on the site does not allow for full data download or easy programmatic processing). This leads to a few problems: first, IATI data does not include grants made in the United States, since it focuses on development assistance (DA) spending. Second, IATI data is updated more infrequently. Third, it may sometimes omit some information that is present in the grants database
Full donor page for donor Bill and Melinda Gates Foundation
| Item | Value |
|---|---|
| Country | |
| Facebook page | rockefelleruniversity |
| Website | http://www.rockefeller.edu |
| Twitter username | rockefelleruniv |
| Wikipedia page | https://en.wikipedia.org/wiki/Rockefeller_University |
| Instagram username | rockefelleruniv |
Full donee page for donee Rockefeller University
| Item | Value |
|---|
| Cause area | Count | Median | Mean | Minimum | 10th percentile | 20th percentile | 30th percentile | 40th percentile | 50th percentile | 60th percentile | 70th percentile | 80th percentile | 90th percentile | Maximum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 21 | 1,684,042 | 3,057,711 | -299,500 | 89,768 | 100,000 | 100,654 | 710,101 | 1,684,042 | 1,697,278 | 3,620,677 | 5,906,943 | 6,639,511 | 13,193,085 |
| Global health | 21 | 1,684,042 | 3,057,711 | -299,500 | 89,768 | 100,000 | 100,654 | 710,101 | 1,684,042 | 1,697,278 | 3,620,677 | 5,906,943 | 6,639,511 | 13,193,085 |
If you hover over a cell for a given cause area and year, you will get a tooltip with the number of donees and the number of donations.
Note: Cause area classification used here may not match that used by donor for all cases.
| Cause area | Number of donations | Total | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global health (filter this donor) | 21 | 64,211,933.50 | -66,031.00 | 19,186,983.00 | 314,114.00 | 19,677,960.00 | 8,513,321.00 | 9,527,620.00 | 1,638,748.00 | 4,908,617.00 | 100,000.00 | 410,601.50 |
| Total | 21 | 64,211,933.50 | -66,031.00 | 19,186,983.00 | 314,114.00 | 19,677,960.00 | 8,513,321.00 | 9,527,620.00 | 1,638,748.00 | 4,908,617.00 | 100,000.00 | 410,601.50 |
Graph of spending by cause area and year (incremental, not cumulative)
Graph of spending by cause area and year (cumulative)
There are no documents associated with this combination of donor and donee.
Graph of all donations (with known year of donation), showing the timeframe of donations
| Amount (current USD) | Amount rank (out of 21) | Donation date | Cause area | URL | Influencer | Notes |
|---|---|---|---|---|---|---|
| -66,031.00 | 20 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support the Isolation of Human Monoclonal Antibodies for HIV Prevention. Isolation of Human Monoclonal Antibodies for HIV Prevention. Investment start date: 9/8/2011 to end date: 5/31/2017. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,612,565.00 | 8 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to clarify molecular mechanisms of IgG transport form mother to child to enhance passive immunization against infections and viruses in the world's most affected populations; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,684,055.00 | 10 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to improve natural product-based lead structure discovery against global health pathogens and to revitalize clinically used natural product based antibiotics for global health; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 13,193,085.00 | 1 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to clinically develop broadly neutralizing anti-HIV antibodies for the prevention of HIV in Sub-Saharan Africa.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,697,278.00 | 9 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to further understanding of metagenomics of the microbiome. Identify Bioactive Metabolites Produced by the Juvenile Human Microbiota. Investment start date: 7/21/2017 to end date: 7/15/2020. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 314,114.00 | 14 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to provide basic information on the ability of adjuvants to increase the diversity of antibodies generated by vaccination; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 6,594,658.00 | 4 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to evaluate the safety, pharmacokinetics and antiretroviral effects of two human anti-HIV monoclonal antibodies, alone and in combination in HIV-infected and HIV-uninfected individuals; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 100,654.00 | 15 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to improve natural product-based lead structure discovery against global health pathogens and to revitalize clinically used natural product based antibiotics for global health; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 12,982,648.00 | 2 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop and evaluate novel antibody based molecules with enhanced in vivo activity for use in prevention of HIV-1 infection; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,684,042.00 | 11 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to improve natural product-based lead structure discovery against global health pathogens and to revitalize clinically used natural product based antibiotics for global health; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 89,768.00 | 19 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to provide technical support to identify what is required to scale up ZMapp production in CHO cells as a potential Ebola therapy..; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 6,639,511.00 | 3 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to evaluate the safety, pharmacokinetics and antiretroviral effects of two human anti-HIV monoclonal antibodies, alone and in combination in HIV-infected and HIV-uninfected individuals; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 100,000.00 | 16 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to improve treatment of African trypanosomiasis in humans and cattle by testing the ability of a drug that was originally developed for treating cancer and heart disease to cure trypanosome infections, and evaluating its mechanism of action.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 5,906,943.00 | 5 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to evaluate the safety, pharmacokinetics and antiretroviral effects of two human anti-HIV monoclonal antibodies, alone and in combination in HIV-infected and HIV-uninfected individuals; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 3,620,677.00 | 7 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support the Isolation of Human Monoclonal Antibodies for HIV Prevention. Isolation of Human Monoclonal Antibodies for HIV Prevention. Investment start date: 9/8/2011 to end date: 5/31/2017. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,638,748.00 | 12 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support the Isolation of Human Monoclonal Antibodies for HIV Prevention. Isolation of Human Monoclonal Antibodies for HIV Prevention. Investment start date: 9/8/2011 to end date: 5/31/2017. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 100,000.00 | 16 | Global health/Reproductive health care | https://iatiregistry.org/publisher/bmgf | -- | to build and test a library of yeast cells that express olfactory receptors encoded with a reporter gene that can react to various metabolic and infectious diseases.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 4,808,617.00 | 6 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to support the Isolation of Human Monoclonal Antibodies for HIV Prevention. Isolation of Human Monoclonal Antibodies for HIV Prevention. Investment start date: 9/8/2011 to end date: 5/31/2017. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 100,000.00 | 16 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to identify single gene mutations that are critical to immunity against bacterial infections to provide insight into a genetic basis for the susceptibility of some children to Tuberculosis and inform a recombinant IFN-y drug therapy; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 710,101.00 | 13 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to elucidate the mechanisms of drug tolerance in Mycobacterium tuberculosis. Drug tolerance in Mycobacterium tuberculosis. Investment start date: 6/1/2006 to end date: 6/1/2007. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -299,499.50 | 21 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to elucidate the mechanisms of drug tolerance in Mycobacterium tuberculosis. Drug tolerance in Mycobacterium tuberculosis. Investment start date: 6/1/2006 to end date: 6/1/2007. Grantee name: Rockefeller University; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |